Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation

Next Previous
Trial Profile

Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 05 Oct 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GSK 137173A (Primary)
  • Indications Herpes zoster
  • Focus Pharmacodynamics

    • Most Recent Events

    • 16 Oct 2020 Planned End Date changed from 1 Mar 2020 to 1 Apr 2021.
    • 03 Jun 2020 Results assessing the safety and immunogenicity of subunit recombinant herpes zoster vaccine (RZV) in lung transplant recipients (LTR) who are known to be at high risk for herpes zoster reactivation compared to other organ transplant recipients, were presented at the 2020 American Transplant Congress.
    • 24 Sep 2019 Planned End Date changed from 5 Mar 2020 to 1 Mar 2020.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top